Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1411073 | 1.00 | TAS1R3 (0.40) | TAS1R3TAS1R1NOS3NOS1NOS2 | |
| SCHEMBL1411360 | 0.90 | MAOB (0.50) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1411363 | 0.90 | MAOB (0.50) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1411065 | 0.88 | SLC6A19 (0.39) | NOS2ALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL1411066 | 0.88 | SLC6A19 (0.39) | NOS2ALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL3784075 | 0.87 | HDAC3 (0.38) | TAS1R3TAS1R1NOS3NOS1NOS2 | |
| SCHEMBL3784072 | 0.87 | HDAC3 (0.38) | TAS1R3TAS1R1NOS3NOS1NOS2 | |
| SCHEMBL10072445 | 0.86 | HDAC1 (0.40) | TAS1R3TAS1R1NOS3NOS1NOS2 | |
| SCHEMBL1411171 | 0.81 | TAS1R3 (0.46) | TAS1R3TAS1R1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1411166 | 0.81 | TAS1R3 (0.46) | TAS1R3TAS1R1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140323531-A1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-8637547-B2 | Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases | CHROMA THERAPEUTICS LTD. (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20130197042-A1 | HDAC INHIBITORS | CHROMA THERAPEUTCS, LTD | 2013-08-01 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| EP-2295410-A1 | HDAC inhibitor | Chroma Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303576-A1 | ENZYME INHIBITORS | HDAC1, HDAC4, HDAC3 | TAS1R3 4072/4885TAS1R1 3522/4885NOS3 1006/4885 |
| US-20140323531-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | TAS1R3 4609/4885TAS1R1 4073/4885NOS3 1449/4885 |
| US-20140155439-A1 | ENZYME INHIBITORS | HDAC4, HDAC1, HDAC3 | TAS1R3 3220/4885TAS1R1 2830/4885NOS3 1805/4885 |
| US-20100010010-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | TAS1R3 4597/4885TAS1R1 4013/4885NOS3 1489/4885 |
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | TAS1R3 4105/4885TAS1R1 3431/4885NOS3 1260/4885 |
| US-20120149736-A1 | ENZYME INHIBITORS | HAT1, HDAC1, NAT1 | TAS1R3 3122/4885TAS1R1 2306/4885NOS3 994/4885 |
| US-20130197042-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | TAS1R3 4609/4885TAS1R1 4073/4885NOS3 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.